Compare GFS & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GFS | PODD |
|---|---|---|
| Founded | 2009 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.5B | 22.1B |
| IPO Year | 2021 | 2007 |
| Metric | GFS | PODD |
|---|---|---|
| Price | $37.21 | $291.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 19 |
| Target Price | $40.80 | ★ $359.00 |
| AVG Volume (30 Days) | ★ 2.6M | 802.6K |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 3.45 |
| Revenue | ★ $6,791,000,000.00 | $2,521,800,000.00 |
| Revenue This Year | $1.13 | $32.55 |
| Revenue Next Year | $6.42 | $20.39 |
| P/E Ratio | ★ N/A | $85.69 |
| Revenue Growth | 0.25 | ★ 27.11 |
| 52 Week Low | $29.77 | $230.05 |
| 52 Week High | $47.69 | $354.88 |
| Indicator | GFS | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 52.61 | 36.99 |
| Support Level | $33.78 | $290.98 |
| Resistance Level | $40.64 | $306.04 |
| Average True Range (ATR) | 1.19 | 9.15 |
| MACD | 0.17 | -2.72 |
| Stochastic Oscillator | 50.55 | 3.67 |
GlobalFoundries is a top-five contract semiconductor manufacturer globally. It was originally the manufacturing arm of Advanced Micro Devices before it was spun out in 2009. The foundry sells chips into a range of end markets including smartphones, PCs, Internet of Things, data centers, automotive, industrial, and so on, but primarily focuses on more mature process technologies. Until 2021, the firm was privately held by Mubadala Investment, the sovereign wealth fund of the United Arab Emirates, which remains its controlling shareholder today. GlobalFoundries merged with Chartered Semiconductor Manufacturing in 2009 and acquired IBM's chipmaking business in 2015. GF is headquartered in Malta, New York, and employs about 13,000 people.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.